SAN DIEGO, CA, USA I October 8, 2024 I Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and ...
The COVID-19 pandemic has reshaped our understanding of coronaviruses. Although overshadowed by SARS-CoV-2, MERS-CoV still poses a public health threat. Cases were sporadic after 2019, with a ...
Hansa Biopharma announces positive results from NICE-01 trial of next generation IgG-cleaving molecule, HNSA-5487: Lund, Sweden Tuesday, October 8, 2024, 11:00 Hrs [IST] Hansa Bio ...
Hansa Biopharma AB, ("Hansa" or the "Company") (NASDAQ STOCKHOLM: HNSA), today announced positive results from a 12-month follow up analysis from the NICE-01 trial of HNSA-5487, the Company's next ...
In AAV, a variety of ANCA syndromes is linked to the same ANCA IgG with diverse concurrent immune events responsible for modifying inflammatory injury.